JIA-HORNG KAOBerg T.2021-09-042021-09-0420190017-5749https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072272463&doi=10.1136%2fgutjnl-2019-319648&partnerID=40&md5=c3126fc8ef50b98ac5127ee6dd5cce36https://scholars.lib.ntu.edu.tw/handle/123456789/581782antiviral therapy; chronic hepatitis; hepatitis B[SDGs]SDG3hepatitis B(e) antigen; nucleoside analog; nucleoside; chronic hepatitis B; decompensated liver cirrhosis; follow up; human; liver cell carcinoma; long term care; Note; priority journal; treatment duration; chronic hepatitis B; Hepatitis B virus; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosidesnote10.1136/gutjnl-2019-319648315270672-s2.0-85072272463